958 related articles for article (PubMed ID: 19149848)
21. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
22. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
[TBL] [Abstract][Full Text] [Related]
25. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
Bello IF; Yuste VJ; Molina MQ; Navarro FH
Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience of prophylactic treatment in von Willebrand disease.
Lethagen S
Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
31. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
Rodeghiero F; Castaman G; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
[TBL] [Abstract][Full Text] [Related]
32. Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates.
Kessler CM; Windyga J; Schwartz BA; Knaub S
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):262-7. PubMed ID: 22322140
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
[TBL] [Abstract][Full Text] [Related]
35. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.
Meriane F; Zerhouni L; Djeha N; Goudemand M; Mazurier C
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1023-9. PubMed ID: 8148475
[TBL] [Abstract][Full Text] [Related]
36. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
37. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
Rivard GE; Aledort L;
Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of a VWF/FVIII concentrate (wilate
Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
[TBL] [Abstract][Full Text] [Related]
40. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
